Cytoxan

"The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma"...

Cytoxan

PATIENT INFORMATION

Advise the patient of the following:

Inform patients of the possibility of myelosuppression,
immunosuppression, and infections. Explain the need for routine blood cell
counts. Instruct patients to monitor their temperature frequently and
immediately report any occurrence of fever [see WARNINGS AND PRECAUTIONS

Advise the patient to report urinary symptoms (patients
should report if their urine has turned a pink or red color) and the need for
increasing fluid intake and frequent voiding [see WARNINGS AND PRECAUTIONS].

Advise patients to contact a health care professional
immediately for any of the following: new onset or worsening shortness of
breath, cough, swelling of the ankles/legs, palpitations, weight gain of more than
5 pounds in 24 hours, dizziness or loss of consciousness [see WARNINGS AND
PRECAUTIONS].

Warn patients of the possibility of developing
non-infectious pneumonitis. Advise patients to report promptly any new or
worsening respiratory symptoms [see WARNINGS AND PRECAUTIONS].

Advise female patients of reproductive potential to use
highly effective contraception during treatment and for up to 1 year after
completion of therapy. There is a potential for harm to a fetus if a patient
becomes pregnant during this period. Patients should immediately contact their
healthcare provider if they become pregnant or if pregnancy is suspected during
this period [see WARNINGS AND PRECAUTIONS and Use in Specific
Populations].

Advise male patients who are sexually active with a
female partner who is or may become pregnant to use condoms during treatment
and for up to 4 months after completion of therapy. There is a potential for
harm to a fetus if a patient fathers a child during this period. Patients
should immediately contact their healthcare provider if their female partner
becomes pregnant or if pregnancy is suspected during this period [see WARNINGS
AND PRECAUTIONS and Use In Specific Populations].

Advise nursing mothers treated with Cytoxan (cyclophosphamide) to discontinue
nursing or discontinue cyclophosphamide, taking into account the importance of
the drug to the mother [see Use In Specific Populations].

Explain to patients that side effects such as nausea,
vomiting, stomatitis, impaired wound healing, amenorrhea, premature menopause,
sterility and hair loss may be associated with cyclophosphamide administration.
Other undesirable effects (including, e.g., dizziness, blurred vision, visual
impairment) could affect the ability to drive or use machines [see ADVERSE
REACTIONS].

Instruct the patient to swallow cyclophosphamide tablets
whole. Do not cut, chew, or crush tablets [see DOSAGE AND ADMINISTRATION].